Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Henagliflozin Proline and Hydrochlorothiazide DDI Study in Healthy Volunteers
NCT06083116Phase 1Completed
- Sponsor
- Hengrui
- Start
- Aug 2019
- Primary completion
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of henagliflozin in type 2 diabetes mellitus (T2DM), sponsored by Hengrui. Primary endpoints: Steady-state Area Under the Curve of Henagliflozin Proline at Day 14, Steady-state Maximum Plasma Concentration of Henagliflozin Proline at Day 14 and 2 more. Started Aug 2019; status: completed.
02
Drugs
henagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06083116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06083116.